Voyager Therapeutics (NASDAQ: VYGR) reported Q1 EPS of ($0.29), $0.09 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $4.83 million versus the consensus estimate of $4.25 million.

For earnings history and earnings-related data on Voyager Therapeutics (VYGR) click here.